Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Bondue, F. Sherer, O. Vosters, G. Van Simaeys, G. Doumont, M. Parmentier, S. Rorive, S. Lacrois, S. Goldman (Brussels, Charleroi, Belgium). PET-CT with ¹⁸F-FDG and ¹⁸F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis. Eur Respir J 2014; 44: Suppl. 58, 3508

Member's Comments

No comment yet.

Related content which might interest you: Lung 18F-FDG uptake correlates with lung function alteration in patients with IPF Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO Source: International Congress 2014 – ILDs 6 Year: 2014 Transient elastography detection of early liver fibrosis in idiopathic pulmonary fibrosis patients Source: International Congress 2014 – ILDs 2 Year: 2014 Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 IPFdatabase – A new tool for a correct application of idiopathic pulmonary fibrosis guidelines Source: International Congress 2014 – ILDs 2 Year: 2014 Comparison of physiological impairment in ILD patients with and without diagnostic IPF features Source: International Congress 2014 – ILDs 4 Year: 2014 Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 2 Year: 2014 Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Evolution of an interstitial lung disease MDT: 5.5 years of data Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2014 – ILDs 1 Year: 2014 The role of CCR2+CD4+T cells in lung fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 High resolution computed tomography (HRCT) can differentiate rapid from slow progressing Idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 2 Year: 2014 6MWT performance by means of Spiropalm in patients affected by fibrotic idiopathic interstitial pneumonias: Preliminary observations Source: International Congress 2014 – ILDs 6 Year: 2014 Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS Source: International Congress 2014 – ILDs 4 Year: 2014 Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Prognostic value of dual-time-point 18F-FDG PET in fibrotic idiopathic interstitial pneumonia Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Density gradient of the lung parenchyma at computed tomography in patients with pulmonary hypertension Source: International Congress 2014 – ILDs 3 Year: 2014 Discovery and validation of peripheral blood gene expression profiles predictive of poor outcome and disease progression in idiopathic pulmonary fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014